Nanobiotix S.A. (NBTX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
NBTX Revenue Growth
Revenue Breakdown (FY 2024)
NBTX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
NBTX Revenue Analysis (2013–2024)
As of May 8, 2026, Nanobiotix S.A. (NBTX) generated trailing twelve-month (TTM) revenue of $47.9 million, reflecting explosive growth of +186.8% year-over-year. The most recent quarter (Q2 2025) recorded $26.6 million in revenue.
Looking at the longer-term picture, NBTX's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $36.2 million in 2023.
Revenue diversification analysis shows NBTX's business is primarily driven by Other Sales (0%), and Services (0%).
When compared to Healthcare sector peers including NVCR (+8.5% YoY), ARAY (-7.9% YoY), and SENS (+78.9% YoY), NBTX has outperformed the peer group in terms of revenue growth. Compare NBTX vs NVCR →
NBTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NBTXCurrent | $48M | +186.8% | - | 589.1% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 ARAY | $459M | -7.9% | +3.7% | 1.7% | |
 SENS | $35M | +78.9% | +48.1% | -193.8% | |
 ONCO | $815,371 | -67.7% | - | -778.2% |
NBTX Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $-11,609,000 | -132.1% | $-11,609,000 | 100.0% | $-68,392,000 | 589.1% |
| 2023 | $36.2M | +658.1% | $36.2M | 100.0% | $-26,779,000 | -74.0% |
| 2022 | $4.8M | +80.4% | $3.8M | 79.4% | $-46,702,000 | -977.8% |
| 2021 | $2.6M | +5194.0% | $2.6M | 100.0% | $-52,579,000 | -1986.4% |
| 2020 | $50K | -26.5% | $50K | 100.0% | $-36,428,000 | -72856.0% |
| 2019 | $68K | -41.4% | $68K | 100.0% | $-46,779,000 | -68792.6% |
| 2018 | $116K | -54.0% | $116K | 100.0% | $-30,067,000 | -25919.8% |
| 2017 | $252K | -83.8% | $-93,623 | -37.2% | $-25,267,041 | -10027.9% |
| 2016 | $1.6M | +486.8% | $1.1M | 72.0% | $-21,854,693 | -1402.6% |
| 2015 | $266K | -72.6% | $-94,068 | -35.4% | $-17,141,647 | -6455.3% |
See NBTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NBTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NBTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNBTX — Frequently Asked Questions
Quick answers to the most common questions about buying NBTX stock.
Is NBTX's revenue growth accelerating or slowing?
NBTX revenue is accelerating at +186.8% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $48M. Growth momentum has increased versus prior periods.
What is NBTX's long-term revenue growth rate?
Nanobiotix S.A.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +186.8% is above this long-term average.
How is NBTX's revenue distributed by segment?
NBTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.